MX2020002057A - Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon. - Google Patents

Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.

Info

Publication number
MX2020002057A
MX2020002057A MX2020002057A MX2020002057A MX2020002057A MX 2020002057 A MX2020002057 A MX 2020002057A MX 2020002057 A MX2020002057 A MX 2020002057A MX 2020002057 A MX2020002057 A MX 2020002057A MX 2020002057 A MX2020002057 A MX 2020002057A
Authority
MX
Mexico
Prior art keywords
signaling pathway
methods
inhibitor
urea cycle
hyperammonemia
Prior art date
Application number
MX2020002057A
Other languages
English (en)
Spanish (es)
Inventor
Xiping Cheng
Haruka Okamoto
Jesper Gromada
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020002057A publication Critical patent/MX2020002057A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2020002057A 2017-08-22 2018-08-21 Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon. MX2020002057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762548632P 2017-08-22 2017-08-22
PCT/US2018/047286 WO2019040471A1 (en) 2017-08-22 2018-08-21 METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING

Publications (1)

Publication Number Publication Date
MX2020002057A true MX2020002057A (es) 2020-07-13

Family

ID=63638351

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002057A MX2020002057A (es) 2017-08-22 2018-08-21 Metodos para tratar trastornos del ciclo de la urea mediante interferencia con la señalizacion del receptor del glucagon.
MX2024011106A MX2024011106A (es) 2017-08-22 2020-02-21 Composiciones para usarse en el tratamiento de trastornos del ciclo de la urea mediante la interferencia con la señalización del receptor de glucagón.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024011106A MX2024011106A (es) 2017-08-22 2020-02-21 Composiciones para usarse en el tratamiento de trastornos del ciclo de la urea mediante la interferencia con la señalización del receptor de glucagón.

Country Status (6)

Country Link
US (2) US12139546B2 (https=)
EP (1) EP3672620A1 (https=)
JP (2) JP7781519B2 (https=)
CA (1) CA3071387A1 (https=)
MX (2) MX2020002057A (https=)
WO (1) WO2019040471A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210642A1 (en) * 2019-04-10 2020-10-15 Camp4 Therapeutics Corporation Methods and compositions for treating urea cycle disorders
CA3205005A1 (en) * 2020-12-16 2022-06-23 Rush University Medical Center Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders
MX2024007790A (es) * 2021-12-22 2024-09-06 Camp4 Therapeutics Corp Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5836308B2 (ja) 1977-02-10 1983-08-08 大塚製薬株式会社 抗体の製造方法
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
JPS56163456A (en) 1980-05-21 1981-12-16 Otsuka Pharmaceut Co Ltd Preparation of antigen
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0658200B1 (en) 1992-08-28 2004-12-22 Novo Nordisk A/S Glucagon receptors
JP2729159B2 (ja) 1994-10-31 1998-03-18 日清製粉株式会社 ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
DE602005006806D1 (de) 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
AU2005272043B2 (en) 2004-07-07 2010-07-29 Merck Sharp & Dohme Corp. Pyrazole amide derivatives, compositions containing such compounds and methods of use
US7625938B2 (en) 2004-07-22 2009-12-01 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
SI1856090T1 (sl) 2005-02-11 2010-02-26 Lilly Co Eli Substituirani derivati tiofena kot antagonisti glukagonskega receptorja, priprava in terapevtske uporabe
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
US7803951B2 (en) 2005-03-30 2010-09-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AR056574A1 (es) 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
CA2649751A1 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compound/glucagon antibody compositions
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20190126460A (ko) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
CL2009000586A1 (es) 2008-03-27 2010-06-04 Lilly Co Eli Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso
EP2291358B1 (en) 2008-05-16 2018-03-28 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
EP2346830B1 (en) 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010071750A1 (en) 2008-12-19 2010-06-24 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
US20110281795A1 (en) 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012188352A (ja) 2009-07-13 2012-10-04 Dainippon Sumitomo Pharma Co Ltd ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩
FR2959129B1 (fr) * 2010-04-21 2013-02-01 Lucane Pharma Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
DK2760479T3 (en) 2011-09-30 2017-07-17 Horizon Therapeutics Llc Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
US9453073B2 (en) 2011-12-02 2016-09-27 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
KR20170062466A (ko) 2014-09-16 2017-06-07 리제너론 파마슈티칼스 인코포레이티드 항-글루카곤 항체 및 그것의 사용

Also Published As

Publication number Publication date
EP3672620A1 (en) 2020-07-01
WO2019040471A1 (en) 2019-02-28
JP2023182691A (ja) 2023-12-26
US12139546B2 (en) 2024-11-12
MX2024011106A (es) 2024-09-18
JP2020531532A (ja) 2020-11-05
WO2019040471A9 (en) 2019-03-21
JP7781519B2 (ja) 2025-12-08
US20250101119A1 (en) 2025-03-27
CA3071387A1 (en) 2019-02-28
US20210130480A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
NZ750953A (en) Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
MX2024011106A (es) Composiciones para usarse en el tratamiento de trastornos del ciclo de la urea mediante la interferencia con la señalización del receptor de glucagón.
AR073978A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
ZA201905866B (en) Anti-c5 antibodies and uses thereof
MX347972B (es) Anticuerpos estables y solubles que inhiben el vegf.
JO3242B1 (ar) طرق علاج داء السكري بمستضادات dll4
SG10201807042YA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
MX361242B (es) Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
JP2014221758A5 (https=)
MX350944B (es) Modulación antisentido de la expresión de gccr.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
TR201908367T4 (tr) Anti̇korlar ve endogsi̇kozi̇tleri̇n bi̇rleşti̇ri̇lmi̇ş terapeuti̇k kullanimi
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
MX2021002710A (es) Anticuerpos anti-c5 humanizados y usos de los mismos.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
TR201901497T4 (tr) Alfa-sinüklein ile ilişkili bozukluklar için terapötik ve teşhis yöntemlerinde kullanıma yönelik antikorlar ve aşılar.
IN2012DN02521A (https=)
MX2016005765A (es) Anticuerpos anti-il-17, un metodo para producir y utilizar los mismos.
MX2013012284A (es) Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
MX2019011252A (es) Anticuerpos anti-c5a y usos de los mismos.
EA201300133A1 (ru) Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ
MX351273B (es) Nuevo anticuerpo anti-ngf humano.
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA202092420A1 (ru) Антитело против pd-l1 и его применение